Your browser is no longer supported. Please, upgrade your browser.
ARQL ArQule, Inc. daily Stock Chart
ARQL [NASD]
ArQule, Inc.
Index- P/E- EPS (ttm)-0.36 Insider Own0.80% Shs Outstand82.92M Perf Week-3.76%
Market Cap446.11M Forward P/E- EPS next Y-0.26 Insider Trans-89.24% Shs Float81.61M Perf Month13.50%
Income-28.20M PEG- EPS next Q0.03 Inst Own68.10% Short Float8.86% Perf Quarter87.46%
Sales4.10M P/S108.81 EPS this Y-19.80% Inst Trans6.73% Short Ratio3.88 Perf Half Y210.98%
Book/sh0.11 P/B48.91 EPS next Y-62.50% ROA-73.10% Target Price6.96 Perf Year320.31%
Cash/sh0.52 P/C10.42 EPS next 5Y5.00% ROE-281.50% 52W Range0.94 - 7.21 Perf YTD226.06%
Dividend- P/FCF- EPS past 5Y-16.50% ROI- 52W High-25.38% Beta0.85
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin- 52W Low472.34% ATR0.46
Employees32 Current Ratio5.40 Sales Q/Q- Oper. Margin- RSI (14)51.31 Volatility6.76% 9.25%
OptionableYes Debt/Eq0.00 EPS Q/Q29.60% Profit Margin- Rel Volume0.59 Prev Close5.21
ShortableYes LT Debt/Eq1.49 EarningsAug 01 BMO Payout- Avg Volume1.86M Price5.38
Recom1.70 SMA20-2.72% SMA5010.10% SMA200108.63% Volume1,093,276 Change3.26%
Jun-18-18Reiterated Needham Buy $6 → $7
May-08-18Reiterated Needham Buy $5 → $6
Apr-05-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-22-18Initiated ROTH Capital Buy $5
Feb-02-18Initiated B. Riley FBR, Inc. Buy $3
Dec-14-17Upgrade Needham Hold → Buy $5
Dec-21-15Upgrade RBC Capital Mkts Sector Perform → Outperform $4 → $5
Dec-09-15Resumed Leerink Partners Mkt Perform
May-12-14Reiterated MLV & Co Hold $3 → $1.75
May-24-13Reiterated MLV & Co Hold $2.25 → $3
Jan-14-13Downgrade MLV & Co Buy → Hold $4 → $2.25
Oct-02-12Downgrade Needham Buy → Hold
Sep-12-12Initiated Burrill Institutional Research Mkt Outperform $10
Jul-30-12Initiated Needham Buy
Mar-15-12Initiated Stifel Nicolaus Buy $13
Jan-31-12Initiated RBC Capital Mkts Outperform $11
May-26-11Initiated Global Hunter Securities Accumulate $11
Apr-01-10Reiterated Mehta Partners Outperform $5 → $9
Oct-13-09Upgrade UBS Sell → Buy
Jul-16-09Downgrade UBS Neutral → Sell
Jul-20-18 09:30AM  Has ArQule (ARQL) Outpaced Other Medical Stocks This Year? Zacks
Jul-18-18 06:18PM  ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018 Business Wire
Jul-14-18 07:16AM  The 4 Best Biotech Stocks of 2018 (So Far) Motley Fool
Jul-13-18 04:01PM  ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Business Wire
Jul-12-18 07:15AM  Free Pre-Market Technical Recap on ArQule and Three Additional Biotech ACCESSWIRE
Jul-11-18 08:15AM  Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares Benzinga
07:00AM  ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock Business Wire
Jul-10-18 04:12PM  ArQule Announces Commencement of Proposed Public Offering of Common Stock Business Wire -8.07%
Jul-02-18 03:06PM  4 Biotech Stocks That Tripled in the First Half of 2018 Motley Fool
Jun-26-18 08:34AM  Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results Benzinga +5.50%
Jun-25-18 07:00AM  ArQule Added to the Russell 2000® Index Business Wire +6.93%
Jun-15-18 09:13AM  Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug Benzinga -6.03%
07:00AM  ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531 Business Wire
Jun-14-18 07:00AM  ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018 Business Wire
Jun-13-18 07:25AM  Initiating Free Research Reports on ArQule and Three Other Biotech Equities ACCESSWIRE +6.37%
Jun-12-18 11:33AM  Oppenheimer Sees New Life In 22-Year-Old ArQule Stock Benzinga
Jun-11-18 08:45AM  Options Traders Expect Huge Moves in ArQule (ARQL) Stock Zacks
08:00AM  The Race to Treat Cancer, ArQule Inc. Continues Progress Across All Pipeline Assets GlobeNewswire
Jun-08-18 08:00AM  Research Report Identifies Qudian Inc., ICICI Bank, Mobile TeleSystems OJSC, ArQule, Alibaba Group Holding, and Arcos Dorados with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -7.79%
Jun-07-18 07:00AM  ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA) Business Wire
May-31-18 07:00AM  ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018 Business Wire
May-25-18 03:45PM  Here's Why ArQule Stock Rose as Much as 16.8% Today Motley Fool +13.69%
May-24-18 07:00AM  ArQule Strengthens Executive Team with Two Key Appointments Business Wire
May-14-18 09:40AM  What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings? Zacks +8.70%
May-10-18 02:06AM  Edited Transcript of ARQL earnings conference call or presentation 7-May-18 1:00pm GMT Thomson Reuters StreetEvents +6.25%
May-07-18 12:11PM  ArQule Inc (NASDAQ:ARQL): What Can We Expect From This High Growth Stock? Simply Wall St.
07:12AM  ArQule: 1Q Earnings Snapshot Associated Press
07:00AM  ArQule Reports First Quarter 2018 Financial Results Business Wire
06:30AM  ArQule, Inc. to Host Earnings Call ACCESSWIRE
May-06-18 06:19PM  The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More Benzinga
Apr-23-18 04:35PM  ArQule to Report First Quarter 2018 Financial Results on May 7, 2018 Business Wire -5.92%
Apr-19-18 07:30AM  Wired News ArQule Inked Exclusive License Deal with Basilea for Derazantinib in the US, EU, Japan and Rest of World ACCESSWIRE -5.75%
Apr-17-18 10:51AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +17.04%
07:00AM  ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China Business Wire
01:16AM  Basilea licenses late-stage oncology drug candidate derazantinib from ArQule GlobeNewswire
Apr-16-18 10:03AM  ArQule, Inc. Is Moving On ASCO Release, Heres Why. Market Exclusive
Apr-13-18 11:38AM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-02-18 07:19AM  Will ArQule (ARQL) Continue to Surge Higher? Zacks +10.42%
Mar-27-18 07:50AM  Recent Analysis Shows Energy Fuels, Vipshop, Tenaris S.A, ArQule, Teekay Offshore Partners, and Chicago Bridge & Iron Company N.V Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-20-18 07:00AM  ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018 Business Wire
Mar-16-18 08:42AM  ArQule (ARQL) in Focus: Stock Moves 15.6% Higher Zacks +8.17%
Mar-15-18 07:00AM  ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting Business Wire +15.56%
Mar-06-18 04:21PM  Edited Transcript of ARQL earnings conference call or presentation 5-Mar-18 2:00pm GMT Thomson Reuters StreetEvents
Mar-05-18 08:27AM  With A -50.74% Earnings Drop, Is ArQule Incs (NASDAQ:ARQL) Performance A Concern? Simply Wall St.
07:15AM  ArQule reports 4Q loss Associated Press
07:00AM  ArQule, Inc. to Host Earnings Call ACCESSWIRE
07:00AM  ArQule Reports Fourth Quarter and Full Year 2017 Financial Results Business Wire
06:50AM  ArQule to Present at the 30th Annual Roth Conference on March 12, 2018 Business Wire
Feb-20-18 07:00AM  ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018 Business Wire
Feb-09-18 07:20AM  Blog Exposure - ArQule Signed License Agreement with Roivant Sciences to Develop Derazantinib In China ACCESSWIRE -9.04%
Feb-08-18 07:00AM  ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018 Business Wire
Feb-07-18 07:07AM  BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China Reuters +5.10%
07:00AM  Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China Business Wire
Dec-28-17 12:46PM  Edited Transcript of ARQL earnings conference call or presentation 9-Nov-17 2:00pm GMT Thomson Reuters StreetEvents
08:56AM  Galectin Therapeutics (GALT) Jumps: Stock Rises 15.1% Zacks
Nov-21-17 07:00AM  ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma Business Wire
Nov-09-17 12:55PM  Is It Time To Buy ArQule Inc (ARQL)? Simply Wall St. +8.18%
07:19AM  ArQule reports 3Q loss Associated Press
07:10AM  ArQule, Inc. to Host Earnings Call ACCESSWIRE
07:00AM  ArQule Reports Third Quarter 2017 Financial Results Business Wire
Nov-08-17 07:00AM  ArQule Announces $9.5 Million Private Placement of Preferred Stock Business Wire +7.84%
Nov-01-17 07:00AM  FDA Grants Rare Pediatric Disease Designation to ArQules Miransertib (ARQ 092) for the Treatment of Proteus Syndrome Business Wire
Oct-26-17 07:00AM  ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017 Business Wire
Oct-16-17 07:00AM  ArQule Announces $15.7 Million Private Placement of Common Stock Business Wire
Sep-19-17 07:00AM  ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017 Business Wire
Aug-12-17 05:06AM  Edited Transcript of ARQL earnings conference call or presentation 4-Aug-17 1:00pm GMT Thomson Reuters StreetEvents
Aug-04-17 10:17PM  ArQule reports 2Q loss Associated Press
07:00AM  ArQule Reports Second Quarter 2017 Financial Results Business Wire
06:40AM  Investor Network: ArQule, Inc. to Host Earnings Call ACCESSWIRE
Jul-21-17 07:00AM  ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017 Business Wire
Jul-11-17 07:00AM  ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies Business Wire
Jun-26-17 11:22AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire +6.84%
Jun-23-17 07:00AM  ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) Business Wire
Jun-07-17 07:00AM  ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases Business Wire
Jun-03-17 09:00AM  ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire
May-18-17 06:00AM  ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) Business Wire +23.02%
May-17-17 05:00PM  ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire
May-03-17 07:46PM  Edited Transcript of ARQL earnings conference call or presentation 3-May-17 1:00pm GMT Thomson Reuters StreetEvents
07:25AM  Investor Network: ArQule, Inc. to Host Earnings Call Accesswire
07:20AM  ArQule reports 1Q loss Associated Press
07:00AM  Arqule Reports First Quarter 2017 Financial Results Business Wire
Apr-26-17 07:00AM  ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531 Business Wire
Apr-19-17 07:00AM  ArQule To Report First Quarter 2017 Financial Results On May 3, 2017 Business Wire
Apr-11-17 07:00AM  ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 Business Wire +8.91%
Apr-05-17 04:20PM  ETFs with exposure to ArQule, Inc. : April 5, 2017 Capital Cube
Mar-28-17 07:00AM  ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017 Business Wire
Mar-27-17 07:36AM  ARQULE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan Business Wire
Mar-21-17 11:28AM  ArQule, Inc. :ARQL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube
Mar-15-17 01:04PM  ARQULE INC Financials
Mar-14-17 02:48PM  ArQule, Inc. :ARQL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
Mar-09-17 04:43PM  ARQULE INC Files SEC form 10-K, Annual Report
Mar-07-17 04:02PM  Edited Transcript of ARQL earnings conference call or presentation 7-Mar-17 2:00pm GMT Thomson Reuters StreetEvents
07:31AM  ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:12AM  ArQule reports 4Q loss Associated Press
07:07AM  Q4 2016 ArQule Inc Earnings Release - Before Market Open
07:00AM  ArQule Reports Fourth Quarter and Full Year 2016 Financial Results Business Wire
Feb-24-17 07:00AM  ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017 Business Wire
Feb-20-17 12:30PM  ArQule Liver Cancer Drug Fails Phase 3 Trial Investopedia
11:07AM  ArQule, Inc. (ARQL)s Liver Cancer Drug Fails: Whats Next? at Insider Monkey
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions. The company's clinical-stage products include Miransertib (ARQ 092), an inhibitor of the AKT serine/threonine kinase in Phase 1/2 clinical trial in rare Overgrowth Diseases, Phase 1 clinical trial in the rare disease, and in Phase 1b in oncology in combination with the hormonal therapy and anastrozole; ARQ 751, a next-generation inhibitor of AKT that is in Phase I clinical trial for solid tumors harboring the AKT1 or PI3K mutation; ARQ 761, a ß-lapachone analog evaluated as a promoter of NQO1-mediated programmed cancer cell death which is in Phase 1/2 clinical trial in multiple oncology; and ARQ 531, an orally bioavailable, potent and reversible inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase 1 for B-cell malignancies refractory to other therapeutic options. It has collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHWARTZ BRIANChief Medical OfficerJun 13Option Exercise3.62200,000724,000245,738Jun 14 09:27 AM
Pucci PaoloChief Executive OfficerJun 08Option Exercise3.95500,0001,975,000920,494Jun 11 04:32 PM
BVF PARTNERS L P/IL10% OwnerMay 30Sale5.001,035,9395,179,799771,305Jun 01 05:13 PM
Nussbaum RanDirectorMay 18Buy3.298,61128,3308,611May 18 05:41 PM
Pucci PaoloChief Executive OfficerMay 18Buy3.3915,00050,849420,494May 18 12:02 PM
ZENNER PATRICK JDirectorMay 14Buy2.968,44624,98782,216May 15 11:37 AM
LINDSAY RONALD MDirectorMay 11Buy2.696,90018,58950,800May 15 11:32 AM
Pucci PaoloChief Executive OfficerMay 10Buy2.641,3003,427405,494May 11 11:23 AM
LINDSAY RONALD MDirectorMay 10Buy2.6723,90063,83743,900May 11 11:17 AM
BVF PARTNERS L P/IL10% OwnerApr 18Sale3.102,230,3736,914,156947,118Apr 20 06:34 PM
BVF PARTNERS L P/IL10% OwnerApr 04Sale2.902,301,5816,674,5851,164,374Apr 06 04:53 PM
Pucci PaoloChief Executive OfficerSep 07Buy1.151,1011,261404,194Sep 08 10:17 AM
Pucci PaoloChief Executive OfficerSep 06Buy1.1516,39718,840403,093Sep 07 10:29 AM
Pucci PaoloChief Executive OfficerSep 05Buy1.1419,15621,844386,696Sep 06 11:47 AM
Pucci PaoloChief Executive OfficerAug 29Buy1.05300315367,540Aug 31 09:52 AM
Pucci PaoloChief Executive OfficerAug 28Buy1.052,9703,115367,240Aug 29 10:10 AM
Pucci PaoloChief Executive OfficerAug 25Buy1.05701736364,270Aug 28 11:51 AM
Pucci PaoloChief Executive OfficerAug 24Buy1.058,7919,212363,569Aug 28 11:51 AM